...
首页> 外文期刊>Nucleic acids research >A rapid, inexpensive yeast-based dual-fluorescence assay of programmed—1 ribosomal frameshifting for high-throughput screening
【24h】

A rapid, inexpensive yeast-based dual-fluorescence assay of programmed—1 ribosomal frameshifting for high-throughput screening

机译:一种快速,廉价的基于酵母的双荧光检测程序,用于程序化的1核糖体移码,可进行高通量筛选

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Programmed ?1 ribosomal frameshifting (?1 PRF) is a mechanism that directs elongating ribosomes to shift-reading frame by 1 base in the 5′ direction that is utilized by many RNA viruses. Importantly, rates of ?1 PRF are fine-tuned by viruses, including Retroviruses, Coronaviruses, Flavivriuses and in two endogenous viruses of the yeast Saccharomyces cerevisiae, to deliver the correct ratios of different viral proteins for efficient replication. Thus, ?1 PRF presents a novel target for antiviral therapeutics. The underlying molecular mechanism of ?1 PRF is conserved from yeast to mammals, enabling yeast to be used as a logical platform for high-throughput screens. Our understanding of the strengths and pitfalls of assays to monitor ?1 PRF have evolved since the initial discovery of ?1 PRF. These include controlling for the effects of drugs on protein expression and mRNA stability, as well as minimizing costs and the requirement for multiple processing steps. Here we describe the development of an automated yeast-based dual fluorescence assay of ?1 PRF that provides a rapid, inexpensive automated pipeline to screen for compounds that alter rates of ?1 PRF which will help to pave the way toward the discovery and development of novel antiviral therapeutics.
机译:程序化的?1核糖体移码(?1 PRF)是一种机制,可将延伸的核糖体沿5'方向的1个碱基转移到阅读框上,这是许多RNA病毒所利用的。重要的是,β1 PRF的比率可以通过病毒(包括逆转录病毒,冠状病毒,黄病毒和酿酒酵母)的两种内源性病毒进行微调,以提供正确比例的不同病毒蛋白进行有效复制。因此,β1PRF为抗病毒治疗提出了新的靶标。 β1PRF的基本分子机制从酵母到哺乳动物都是保守的,使酵母可用作高通量筛选的逻辑平台。自从最初发现?1 PRF以来,我们对监测?1 PRF的测定方法的优势和陷阱的理解已经发展。这些措施包括控制药物对蛋白质表达和mRNA稳定性的影响,以及最小化成本和对多个加工步骤的需求。在这里,我们描述了基于自动酵母的α1PRF双重荧光检测技术的发展,该方法提供了一种快速,廉价的自动化管道来筛选可改变α1PRF速率的化合物,这将有助于发现和开发p1 PRF。新型抗病毒疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号